No impairment of peripheral deposition in novel asthmatics treated with an MDI corticosteroid with spacer

Respiratory Medicine

Volumn 97, Issue 2, 2003, Pages 152-158

  Saari, S Marisanna ^a   Vidgren, M T ^b   Turjanmaa, V M H ^a   Koskinen, M O ^a   Nieminen, M M ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Asthma; Deposition; Inhaled corticosteroids; Liposome

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; LIPOSOME; TECHNETIUM 99M;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG FORMULATION; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; LUNG SCINTISCANNING; METERED DOSE INHALER; NEBULIZER; PRESSURE CHAMBER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS;

EID: 0037291335     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2003.1428     Document Type: Article

References (38)

1. Howart PH. Small airway inflammation and asthma. Int J Pract Pract 1998; 96 (Suppl): 15-22.
2. Kraft M. The distal airways: are they important in asthma. Eur Respir J 1999; 14: 1403-1417.
3. Bjermer L. History and future of treating asthma as a systemic and small airways disease. Respir Med 2001; 95: 703-719.
4. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102: 531-538.
5. Dahl R, Bjermer L. Nordic consensus report on asthma management. Respir Med 2000; 94: 299-327.
6. British Thoracic Society. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: S1-S21.
7. Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K. et al. Comparison of a beta-2-agonist, terbutaline, with an inhaled corticosteroid, budenoside, in newly detected asthma. N Engl J Med 1991; 325: 388-392.
8. Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budenoside in patients with mild asthma. N Engl J Med 1994; 331: 700-705.
9. Durham SR, Till SJ, Corrigan CJ. T lymphocytes in asthma: bronchial versus peripheral responses. J Allergy Clin Immunol 2000; 105: 20-36.
10. 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 1998; 113: 1573-1579.
11. Melchor R, Biddiscombe MF, Mak VHF, Short MD, Spiro SG. Lung deposition patterns of directly labeled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48: 506-511.
12. Pavia D, Thomson ML, Clarce SW, Shannon HS. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax 1977; 32: 194-197.
13. 20, and exacerbations. Respir Med 1994; 88: 613-621.
14. Waldrep JC, Keyhani K, Black M, Knight V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994; 105: 106-110.
15. Waldrep JC, Gilbert BE, Knight BN, Black Scherer PW, Knight V, Eschenbacher W. Pulmonary delivery of beclomethasone liposome aerosol. Chest 1997; 111: 316-323.
16. 99mtechnetium labeled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int J Pharm 1995; 115: 209-216.
17. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
18. Waldrep JC, Scherer PW, Hess GD, Black MB, Scherer PW, Knight V. Nebulized glucocorticoids in liposomes: aerosol characteristics and human dose estimates. J Aerosol Med 1994; 7: 135-144.
19. Saari M, Vidgren MT, Koskinen MO, Turjanmaa VMH, Nieminen MM. Pulmonary distribution and clearance of two beclomethasone formulations in healthy volunteers. Int J Pharm 1999; 181: 1-9.
20. Nieminen MM, Lahdensuo A, Kellomäki L, Karvonen J, Muittari A. Methacholine bronchial challenge using dosimeter with controlled tidal breathing. Thorax 1988; 43: 896-900.
21. Nieminen MM, Holli H, Lahdensuo A, Muittari A, Karvonen. Aerosol deposition in automatic dosimeter nebulization. J Eur J Respir Dis 1987; 71: 145-152.
22. Smaldone GC, Walser L, Perry RJ, Ilowite JS, Bennett WD, Greco M. Generation and administration of aerosols for medical and physiological research studies. J Aerosol Med 1989; 2: 81-87.
23. Smaldone GC, Perry Rj, Bennett WD, Messina MS, Swang J, Ilowite J. Interpretation of '24-hour lung retention' in studies of mucociliary clearance. J Aerosol Med 1988; 1: 11-20.
24. Macey DJ, Marshall R. Absolute quantitation of radiotracer uptake in the lungs using a gamma camera. J Nucl Med 1982; 23: 731-735.
25. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG. Respiratory pathophysiologic responses. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100: 44-51.
26. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-875.
27. Leach CL. Improved delivery of inhaled steroids to the large and small airways. Respir Med 1998: 92 (Suppl A): 3-8.
28. Yanai M, Hatazawa J, Ojima F, Sasaki H, Itoh M, Ido T. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 11: 1342-1348.
29. Pavia D, Bateman JRM, Sheahan NF, Agnew JE, Clarke SW. Tracheobronchial mucociliary clearance in asthma: impairment during remission. Thorax 1985; 40: 171-175.
30. Bateman JRM, Pavia D, Sheahan NF, Agnew JE, Clarce SW. Impaired tracheobronchial clearance in patients with mild asthma. Thorax 1983; 38: 463-467.
31. Howarth PH. What is the nature of asthma and where are the therapeutic targets? Respir Med 1997; 91 (Suppl A): 2-8.
32. Thompson PJ. Drug delivery to the small airways. Am J Crit Care Med 1998; 157: S199-S202.
33. Saari SM, Vidgren MT, Herrala J, Turjanmaa VHM, Koskinen MO, Nieminen MM. The possibilities of formoterol to enhance the peripheral lung deposition of the inhaled liposome corticosteroids. Respir Med (in press).
34. Howarth PH. Why particle size should affect clinical response to inhaled therapy. J Aerosol Med 2001; 14 (Suppl 1): S27-S34.
35. Howarth PH. The relevance of site of airway inflammation in asthma and targeted aerosol delivery. Int J Clin Pract 1999; 106 (Suppl): 3-10.
36. Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997; 10: 1496-1499.
37. Berridge MS, Lee Z, Heald DL. Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Design 2000; 6: 1631-1651.
38. Nelson H, Newman K. Prevention of asthma exacerbations by HFA flunisolide in adults and adolescents with mild-to-moderate asthma. J Allergy Clin Immunol 2001; 107: abstract 350.